Additionally, there are several small-molecule VEGFR-2 inhibitors (including Sorafenib, sunitinib, pazopanib, vandetanib, axitinib, regorafenib, cabozantinib, lenvatinib, tivozanib) that have been approved by the US FDA as anti-cancer medicines for clinical application29. The gene discussed is KDR; the disease is cancer.